(ANIP) ANI Pharmaceuticals - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.734m USD | Total Return: 25.3% in 12m

Generic Drugs, Branded Drugs, Injectables, Softgels
Total Rating 61
Safety 78
Buy Signal 0.09
Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.3
Market Cap: 1.73B
Avg Turnover: 25.5M USD
ATR: 3.48%
Peers RS (IBD): 37.7
Risk 5d forecast
Volatility33.7%
Rel. Tail Risk-5.72%
Reward TTM
Sharpe Ratio0.51
Alpha0.21
Character TTM
Beta0.404
Beta Downside1.692
Drawdowns 3y
Max DD28.66%
CAGR/Max DD0.98
EPS (Earnings per Share) EPS (Earnings per Share) of ANIP over the last years for every Quarter: "2021-03": 1.04, "2021-06": 0.67, "2021-09": 1.01, "2021-12": 0.54, "2022-03": -0.12, "2022-06": 0.13, "2022-09": 0.64, "2022-12": 0.76, "2023-03": 1.17, "2023-06": 1.28, "2023-09": 1.27, "2023-12": 1, "2024-03": 1.21, "2024-06": 1.02, "2024-09": 1.34, "2024-12": -0.55, "2025-03": 0.69, "2025-06": 0.36, "2025-09": 2.04, "2025-12": 2.33,
EPS CAGR: 58.42%
EPS Trend: 36.1%
Last SUE: 0.48
Qual. Beats: 0
Revenue Revenue of ANIP over the last years for every Quarter: 2021-03: 54.521, 2021-06: 48.625, 2021-09: 52.061, 2021-12: 60.929, 2022-03: 64.477, 2022-06: 73.855, 2022-09: 83.821, 2022-12: 94.232, 2023-03: 106.786, 2023-06: 116.547, 2023-09: 131.829, 2023-12: 131.654, 2024-03: 137.43, 2024-06: 138.04, 2024-09: 148.332, 2024-12: 190.574, 2025-03: 197.122, 2025-06: 211.371, 2025-09: 227.813, 2025-12: 247.06,
Rev. CAGR: 43.08%
Rev. Trend: 98.4%
Last SUE: 2.99
Qual. Beats: 5

Warnings

No concerns identified

Tailwinds

Garp

Description: ANIP ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a biopharmaceutical company operating in the United States and internationally. The company develops, manufactures, and markets both branded and generic pharmaceutical products.

Its product portfolio includes injectables, softgel capsules, and specific branded products like Cortrophin gel, ILUVIEN, and YUTIQ. The company also produces various dosage forms, including oral solids, semi-solids, liquids, and topicals, as well as controlled substances.

ANI Pharmaceuticals distributes its products through a diverse network, including wholesalers, retail chains, and specialty pharmacies. The pharmaceutical sector often relies on a multi-channel distribution strategy to reach various healthcare providers and patients.

For more detailed analysis of ANIPs market position and financial health, consider exploring ValueRay.

Headlines to Watch Out For
  • Cortrophin Gel sales growth boosts revenue
  • Generic drug approvals expand product portfolio
  • Manufacturing costs impact profit margins
  • Regulatory scrutiny affects drug development timeline
  • Competition from other generics erodes market share
Piotroski VR‑10 (Strict) 7.5
Net Income: 75.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 5.20 > 1.0
NWC/Revenue: 53.77% < 20% (prev 54.36%; Δ -0.59% < -1%)
CFO/TA 0.13 > 3% & CFO 185.2m > Net Income 75.9m
Net Debt (39.6m) to EBITDA (225.7m): 0.18 < 3
Current Ratio: 2.71 > 1.5 & < 3
Outstanding Shares: last quarter (21.2m) vs 12m ago 9.17% < -2%
Gross Margin: 69.08% > 18% (prev 0.59%; Δ 6.85k% > 0.5%)
Asset Turnover: 64.86% > 50% (prev 47.86%; Δ 17.00% > 0%)
Interest Coverage Ratio: 3.06 > 6 (EBITDA TTM 225.7m / Interest Expense TTM 43.9m)
Altman Z'' 2.75
A: 0.33 (Total Current Assets 753.1m - Total Current Liabilities 278.1m) / Total Assets 1.44b
B: -0.02 (Retained Earnings -23.1m / Total Assets 1.44b)
C: 0.10 (EBIT TTM 134.3m / Avg Total Assets 1.36b)
D: -0.02 (Book Value of Equity -22.1m / Total Liabilities 899.7m)
Altman-Z'' Score: 2.75 = A
Beneish M -3.14
DSRI: 0.88 (Receivables 281.1m/221.7m, Revenue 883.4m/614.4m)
GMI: 0.86 (GM 69.08% / 59.27%)
AQI: 0.80 (AQ_t 0.43 / AQ_t-1 0.54)
SGI: 1.44 (Revenue 883.4m / 614.4m)
TATA: -0.08 (NI 75.9m - CFO 185.2m) / TA 1.44b)
Beneish M-Score: -3.14 (Cap -4..+1) = AA
What is the price of ANIP shares? As of April 09, 2026, the stock is trading at USD 79.01 with a total of 705,175 shares traded.
Over the past week, the price has changed by +4.02%, over one month by +5.61%, over three months by -2.50% and over the past year by +25.31%.
Is ANIP a buy, sell or hold? ANI Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ANIP.
  • StrongBuy: 3
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ANIP price?
Analysts Target Price 110.6 40%
ANI Pharmaceuticals (ANIP) - Fundamental Data Overview as of 08 April 2026
P/E Trailing = 23.253
P/E Forward = 8.4246
P/S = 1.9627
P/B = 3.0774
P/EG = 1.06
Revenue TTM = 883.4m USD
EBIT TTM = 134.3m USD
EBITDA TTM = 225.7m USD
Long Term Debt = 599.8m USD (from longTermDebt, last quarter)
Short Term Debt = 17.3m USD (from shortTermDebt, last quarter)
Debt = 617.0m USD (corrected: LT Debt 599.8m + ST Debt 17.3m)
Net Debt = 39.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.07b USD (1.73b + Debt 617.0m - CCE 285.6m)
Interest Coverage Ratio = 3.06 (Ebit TTM 134.3m / Interest Expense TTM 43.9m)
EV/FCF = 16.08x (Enterprise Value 2.07b / FCF TTM 128.4m)
FCF Yield = 6.22% (FCF TTM 128.4m / Enterprise Value 2.07b)
FCF Margin = 14.54% (FCF TTM 128.4m / Revenue TTM 883.4m)
Net Margin = 8.59% (Net Income TTM 75.9m / Revenue TTM 883.4m)
Gross Margin = 69.08% ((Revenue TTM 883.4m - Cost of Revenue TTM 273.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 49.07%)
Tobins Q-Ratio = 1.43 (Enterprise Value 2.07b / Total Assets 1.44b)
Interest Expense / Debt = 3.70% (Interest Expense 22.8m / Debt 617.0m)
Taxrate = 12.67% (3.99m / 31.5m)
NOPAT = 117.3m (EBIT 134.3m * (1 - 12.67%))
Current Ratio = 2.71 (Total Current Assets 753.1m / Total Current Liabilities 278.1m)
Debt / Equity = 1.14 (Debt 617.0m / totalStockholderEquity, last quarter 540.7m)
Debt / EBITDA = 0.18 (Net Debt 39.6m / EBITDA 225.7m)
Debt / FCF = 0.31 (Net Debt 39.6m / FCF TTM 128.4m)
Total Stockholder Equity = 487.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.57% (Net Income 75.9m / Total Assets 1.44b)
RoE = 15.55% (Net Income TTM 75.9m / Total Stockholder Equity 487.9m)
RoCE = 12.35% (EBIT 134.3m / Capital Employed (Equity 487.9m + L.T.Debt 599.8m))
RoIC = 10.70% (NOPAT 117.3m / Invested Capital 1.10b)
WACC = 6.31% (E(1.73b)/V(2.35b) * Re(7.40%) + D(617.0m)/V(2.35b) * Rd(3.70%) * (1-Tc(0.13)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 5.10%
[DCF] Terminal Value 79.15% ; FCFF base≈96.1m ; Y1≈63.1m ; Y5≈28.9m
[DCF] Fair Price = 35.57 (EV 836.9m - Net Debt 39.6m = Equity 797.3m / Shares 22.4m; r=6.31% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 36.15 | EPS CAGR: 58.42% | SUE: 0.48 | # QB: 0
Revenue Correlation: 98.41 | Revenue CAGR: 43.08% | SUE: 2.99 | # QB: 5
EPS next Quarter (2026-06-30): EPS=2.18 | Chg7d=-0.021 | Chg30d=+0.099 | Revisions Net=+2 | Analysts=7
EPS current Year (2026-12-31): EPS=9.05 | Chg7d=-0.005 | Chg30d=+0.409 | Revisions Net=+4 | Growth EPS=+14.8% | Growth Revenue=+23.0%
EPS next Year (2027-12-31): EPS=10.52 | Chg7d=+0.129 | Chg30d=+0.213 | Revisions Net=+0 | Growth EPS=+16.2% | Growth Revenue=+12.5%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.6% (Discount Rate 7.9% - Earnings Yield 4.3%)
[Growth] Growth Spread = +20.9% (Analyst 24.6% - Implied 3.6%)
External Resources
Dataroma Stockcircle